ALLO Earnings & Financial Statements
Allogene Therapeutics, Inc.
$1.46
+$0.06(+4.29%)
30
Overall
60
Value
9
Tech
21
Quality
Market Cap
$483.69M
Volume
10.60M
52W Range
$1.04 - $4.46
Target Price
$8.30
ALLO earnings and financial statements: Allogene Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ALLO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $22.0K | $95.0K | $156.0K | $38.49M |
| Operating income | -$209.31M | -$273.20M | -$327.74M | -$335.54M | -$255.79M |
| EBITDA | -$177.45M | -$243.33M | -$334.68M | -$321.24M | -$169.74M |
| Net income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | -$182.05M |
| EPS (diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.32 | $-1.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $415.90M | $548.71M | $642.84M | $821.58M | $1.04B |
| Total liabilities | $123.36M | $126.53M | $130.60M | $154.70M | $122.23M |
| Shareholders’ equity | $292.54M | $422.18M | $512.23M | $666.88M | $916.41M |
| Cash and equivalents | $51.69M | $75.22M | $83.16M | $61.90M | $173.31M |
| Long-term debt | $75.05M | $83.25M | $88.35M | $95.12M | $69.93M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$149.25M | -$200.30M | -$237.73M | -$220.52M | -$184.81M |
| Capital expenditure | -$386.0K | -$694.0K | -$1.52M | -$5.19M | -$21.45M |
| Free cash flow | -$149.63M | -$200.99M | -$239.25M | -$225.71M | -$206.26M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALLO | $1.46 | +4.3% | 10.60M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Allogene Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW